Released Nov 12, 2024, after the close
10-Q filed Nov 12, 2024, 43 days after period end · 0001493152-24-044841
Q3 2024 · 10-Q
Revenue$487.00K$487.00K +854.9% vs Q3 2023+936.2% vs Q2 2024
Net Income-$26.60M-$26.60M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$73.70-$73.70 N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$547,000N/M
Operating Income-$2,259,000N/M
Operating Cash Flowderived-$6,285,000N/M
Free Cash Flowderived-$6,304,000N/M
Margins · derived
Gross margin112.3%+247.6 pt vs Q3 2023
Operating margin-463.9%+10330.3 pt vs Q3 2023
Net margin-5462.8%+5499.9 pt vs Q3 2023
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $487.00K | $51.00K | $0.00 | — |
| Net Income | -$26.60M | -$5.59M | -$7.32M | -$85.99M |
| EPS Diluted | -$73.70 | -$1.03 | -$2.49 | -$34.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR